Alyeska Investment Group
SGNT

Alyeska Investment Group’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Alyeska Investment Group’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-197,859
Closed -$5.12M – 519
2014
Q2 		$5.12M Buy
+197,859
New +$4.39M 0.11% 230

Other funds holding SGNT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Alyeska Investment Group's SGNT Position: Q3 2014 in Review

Alyeska Investment Group sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2014, closing a stake of 197,859 shares — an estimated $5.12M sold.

Alyeska Investment Group first reported a position in SGNT in Q2 2014 and held it in 1 quarter. The position peaked at $5.12M in Q2 2014. 114 funds tracked by Wall St. Rank hold SGNT as of Q3 2014.

  • Alyeska Investment Group reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2014 after selling out during the quarter.
  • Alyeska Investment Group sold 197,859 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2014, an estimated $5.12M.
  • Alyeska Investment Group first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2014 and held it in 1 quarter.
  • Alyeska Investment Group's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $5.12M in Q2 2014.
  • 114 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2014.

Based on Alyeska Investment Group's 13F filing for Q3 2014, filed 14 Nov 2014.